MONJUVI (tafasitamab-cxix) for injection
MONJUVI (tafasitamab-cxix) is a prescription medicine used in combination with lenalidomide to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). FDA approved tafasitamab-cxix (brand name MONJUVI) is not (yet) registered or available in India. The access to the drug is provided as per Name Patient Program respecting the regulatory framework as desired by local authorities.
Home | tafasitamab-cxix for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
MONJUVI (tafasitamab-cxix) for injection
Tafasitamab, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma.
MONJUVI is a prescription medicine given:
• in combination with lenalidomide, to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
• in combination with a lenalidomide and rituximab, to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.
MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.
It is not known if MONJUVI is safe and effective in children
Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.
Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.
Drug (Brand / Generic): MONJUVI® (tafasitamab-cxix) for injection, for intravenous use Initial U.S. Approval: 2020
Current Indication: treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Approval Date: 2020
For injection: 200 mg of tafasitamab-cxix as lyophilized powder in single-dose vial for reconstitution.
Find Reference Updates
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is a trusted pharmaceutical access facilitator in India, aligned with Good Distribution Practice (GDP) standards. We provide specialized support to help patients and healthcare professionals access MONJUVI (tafasitamab-cxix) for injection, an internationally approved therapy.
Where MONJUVI is not commercially available in India, we facilitate access through regulated pathways such as the Named Patient Supply (NPS) framework. Each request is carefully managed in compliance with applicable regulations and requires a valid prescription and, where necessary, import authorization.
Get Access to FDA approved tafasitamab-cxix (brand name MONJUVI) in India.
We can help patients access approved MONJUVI (tafasitamab-cxix) for injection in the following cities across India – Ahmedabad, Bangalore, Surat, Kolkata, Pune, Indore, Nagpur, Agra, Kanpur, Patna, Coimbatore, Kochi, Delhi, Gurugram, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Bhopal, Mumbai, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Agartala, Lucknow, Dehradun, Gairsain. Aizawal, Aurangabad, Barshi, Cachar, Dibrugarh, Karungapally, Kollam, Meghalaya, Mizoram, Sikkim, Pondichery, Punjab, Tripura, New Delhi, Agra, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad.MONJUVI (tafasitamab-cxix) for injection – Sourcing & Access Support
Alleviare India provides assistance in facilitating access to MONJUVI (tafasitamab-cxix) for injection, a prescribed oncology medication, through trusted international supply channels. We support patients and healthcare providers in identifying appropriate supply options for medicines that may have limited local availability, in accordance with applicable regulations.Access is provided only against a valid prescription, and services are offered under the Named Patient Supply (NPS) framework. Alleviare India may also assist in connecting with authorized supply channels where appropriate.Pricing & Availability in India
For information on the availability and indicative pricing of MONJUVI (tafasitamab-cxix) for injection, please contact us directly.The cost of the medicine is determined by the manufacturer. Additional charges may include Named Patient support service fees, shipping costs, and applicable local taxes, in accordance with regulatory requirements.Is MONJUVI available in India?
Meet Our Medicine Access Expert for availability of Truqap medications.At Alleviare, we prioritize transparency while supporting patients, healthcare professionals, and institutions in accessing genuine medicines through trusted global sources in Canada, Europe, the USA, and Australia. We provide tailored assistance to facilitate access to prescribed therapies, including those not readily available locally, in full compliance with applicable regulatory requirements.Access is facilitated under the Named Patient Supply (NPS) framework. We also offer guidance on the availability and indicative pricing of prescribed medications across major cities in India, including Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune.Medicine: MONJUVI (tafasitamab-cxix) for injection (subject to prescription and regulatory guidelines)Start Your Access JourneyEmail: info@alleviareindia.com, Mobile: +91 9818274099 / 9289711088Is tafasitamab-cxix available in India?Yes, FDA approved tafasitamab-cxix (brand name MONJUVI) is not (yet) registered or available in India but on request Indian patient can buy MONJUVI at the lowest price.What documents are required to import MONJUVI to India?
To import MONJUVI (tafasitamab-cxix), patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
- Valid prescription from the doctor.
- Import permit, if applicable.